AXIM Biotechnologies, Inc. and Medical Marijuana, Inc. have entered into a strategic alliance to research and develop applications for AXIM's patent covering water-soluble cannabinoids. The collaboration centers on U.S. Patent No. 11,542,226 B2, which addresses a fundamental limitation of traditional cannabinoids: their inability to dissolve in water, significantly impairing absorption by the body.
Under the agreement, AXIM assigned Medical Marijuana Inc. a 50% right, title, and economic interest in the patent and all associated intellectual property. This includes rights to existing and future patents, licensing proceeds, and claims for past infringement. Medical Marijuana Inc. paid $600,000 for this interest through a secured promissory note. Concurrently, the companies entered a consulting agreement where AXIM will provide research and development services focused on developing applications for the patent technology, with Medical Marijuana Inc. paying AXIM $62,500 monthly for these services.
The technological breakthrough described in the patent involves molecular engineering that links cannabinoids to complementary compounds, creating polyfunctional cannabinoids that are more than 300 times more water-soluble than natural cannabinoids. This dramatically increased solubility enables significantly improved absorption and therapeutic delivery. According to Catalina Valencia, AXIM President, "The water solubility of CBD and other cannabinoids is a significant development for the improved administration and increased potency of cannabinoids."
The alliance could have substantial implications for medical treatment development. Valencia noted that the patent technology could result in developing a drug or treatment, likely in sublingual form, able to treat various conditions including anxiety or seizures. The engineered polyfunctional constructs are designed to produce more potent responses than individual cannabinoid molecules, potentially allowing for lower therapeutic doses while avoiding toxic side effects associated with higher concentrations.
Dr. Scott, MJNA Chairman and President, expressed confidence in the partnership, stating, "The potential for developing enhanced administration of water soluble CBD and other cannabinoids for certain ailments and conditions is a major development for MJNA." Medical Marijuana Inc. brings existing market knowledge and relationships in the cannabinoid arena to the collaboration.
The consulting agreement has an initial non-cancellable term of one year expiring in January 2027, continuing month-to-month thereafter until terminated by either party with 90-day written notice. The technology offers treatment potential for conditions where traditional oil-based cannabinoids have demonstrated limited bioavailability, including development of sublingual applications for anxiety and other indications. For more information about AXIM's diagnostic technologies, visit https://www.aximbiotech.com.
